Because predicting arrhythmic or heart failure events in these patients remains challenging, incorporating hs-cTnT into risk models may allow the earlier identification of high-risk individuals who could benefit from intensified monitoring, prophylactic device implantation, or escalation of immunosuppressive therapy [15]. Here, TNNT2 is linked to heart failure.